Mesa Laboratories (NASDAQ:MLAB) Sets New 1-Year High – What’s Next?

Mesa Laboratories, Inc. (NASDAQ:MLAB)’s stock price reached a new 52-week high during trading on Monday . The stock traded as high as $129.66 and last traded at $127.6650, with a volume of 153074 shares. The stock had previously closed at $128.93.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Weiss Ratings upgraded Mesa Laboratories from a “sell (d)” rating to a “hold (c-)” rating in a research report on Tuesday, August 11th. Wells Fargo & Company boosted their price target on Mesa Laboratories from $94.00 to $110.00 and gave the stock an “equal weight” rating in a research report on Friday, August 14th. Finally, Wall Street Zen downgraded Mesa Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 15th. Three investment analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $110.00.

Mesa Laboratories Stock Down 0.9%

The stock has a market capitalization of $716.63 million, a price-to-earnings ratio of 152.22 and a beta of 0.92. The business’s 50-day moving average is $104.42 and its two-hundred day moving average is $98.63. The company has a quick ratio of 1.32, a current ratio of 1.79 and a debt-to-equity ratio of 0.73.

Mesa Laboratories (NASDAQ:MLAB) last released its quarterly earnings data on Monday, August 10th. The medical instruments supplier reported $2.68 EPS for the quarter. The company had revenue of $60.14 million during the quarter. Mesa Laboratories had a net margin of 1.92% and a return on equity of 22.72%.

Mesa Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Monday, August 31st will be given a $0.16 dividend. The ex-dividend date is Monday, August 31st. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.5%. Mesa Laboratories’s dividend payout ratio is 76.19%.

Insider Transactions at Mesa Laboratories

In other Mesa Laboratories news, CAO Lyndsey Elizabeth Crennen sold 442 shares of the business’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $89.50, for a total transaction of $39,559.00. Following the transaction, the chief accounting officer owned 2,020 shares of the company’s stock, valued at approximately $180,790. The trade was a 17.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director John James Sullivan sold 7,093 shares of the company’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $112.80, for a total value of $800,090.40. Following the completion of the sale, the director owned 17,834 shares of the company’s stock, valued at approximately $2,011,675.20. The trade was a 28.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 15,370 shares of company stock valued at $1,570,213. 2.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of MLAB. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Mesa Laboratories by 5,366.7% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 328 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 322 shares during the period. Caitong International Asset Management Co. Ltd purchased a new position in Mesa Laboratories during the fourth quarter worth about $27,000. Kestra Advisory Services LLC purchased a new position in Mesa Laboratories during the fourth quarter worth about $55,000. BNP Paribas Financial Markets boosted its holdings in Mesa Laboratories by 30.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,029 shares of the medical instruments supplier’s stock valued at $69,000 after purchasing an additional 243 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in Mesa Laboratories by 432.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 842 shares of the medical instruments supplier’s stock valued at $79,000 after purchasing an additional 684 shares during the last quarter. Institutional investors and hedge funds own 90.60% of the company’s stock.

About Mesa Laboratories

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.